Summit Therapeutics plc (SMMT)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:14AM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 3.17B |
| Enterprise value | 3.12B |
| Trailing P/E | 11.87 |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | N/A |
| Price/book (mrq) | 71.61 |
| Enterprise value/revenue | 6.43k |
| Enterprise value/EBITDA | -5.32 |
Trading information
Stock price history
| Beta (5Y monthly) | -1.13 |
| 52-week change 3 | 168.45% |
| S&P500 52-week change 3 | 26.36% |
| 52-week high 3 | 5.3900 |
| 52-week low 3 | 1.5000 |
| 50-day moving average 3 | 4.0710 |
| 200-day moving average 3 | 2.9307 |
Share statistics
| Avg vol (3-month) 3 | 2.26M |
| Avg vol (10-day) 3 | 2.15M |
| Shares outstanding 5 | 701.98M |
| Implied shares outstanding 6 | 701.98M |
| Float 8 | 73.34M |
| % held by insiders 1 | 88.14% |
| % held by institutions 1 | 7.23% |
| Shares short (30 Apr 2024) 4 | 23.4M |
| Short ratio (30 Apr 2024) 4 | 14.37 |
| Short % of float (30 Apr 2024) 4 | 28.07% |
| Short % of shares outstanding (30 Apr 2024) 4 | 3.33% |
| Shares short (prior month 28 Mar 2024) 4 | 21.81M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -33.27% |
| Return on equity (ttm) | -130.59% |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -114.75M |
| Net income avi to common (ttm) | -116.03M |
| Diluted EPS (ttm) | 0.3800 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 156.68M |
| Total cash per share (mrq) | 0.22 |
| Total debt (mrq) | 109.52M |
| Total debt/equity (mrq) | 247.73% |
| Current ratio (mrq) | 6.97 |
| Book value per share (mrq) | 0.06 |
Cash flow statement
| Operating cash flow (ttm) | -93.76M |
| Levered free cash flow (ttm) | -527.61M |
© 2024 Yahoo. All rights reserved.